Recent studies have demonstrated that AIP serves as a significant biomarker for predicting unfavorable metabolic conditions, including diabetes and insulin resistance (Yin et al., 2023; Zheng et al., 2023), metabolic syndrome (Li et al., 2021), and Visceral Adiposity (Zhou et al., 2018; Shen et al., 2018). The gene discussed is AIP; the disease is Insulin resistance.